A comparative study of dydrogesterone and micronized progesterone for luteal phase support during in vitro fertilization (IVF) cycles. (3rd March 2016)

• Record Type: Journal Article
• Authors: Saharkhiz, Nasrin; Zamaniyan, Marzieh; Salehpour, Saghar; Zadehmodarres, Shahrzad; Hoseini, Sedighe; Cheraghi, Leila; Seif, Samira; Baheiraei, Nafiseh
• Is Part Of: Gynecological endocrinology. Volume 32:Number 3(2016:Mar.)
• Page Start: 213
• Page End: 217
• Publication Date: 2016-03-03
• Subjects: Dydrogesterone -- in vitro fertilization -- luteal-phase support -- micronized progesterone -- progesterone; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.3109/09513590.2015.1110136
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: The aim of the present study was to compare the efficacy, tolerability and patients' satisfaction after the use of oral dydrogesterone with vaginal micronized progesterone for luteal-phase support (LPS) among infertile women undergoing in vitro fertilization (IVF). A total of 210 women (aged 20–40 years old) with a history of infertility, who underwent controlled ovarian stimulation for fresh intra-cytoplasmic sperm injection-embryo transfer cycles, were included in the study. Consequently, they were randomized to receive LPS with dydrogesterone 20 mg twice daily ( n = 96) or micronized progesterone 400 mg twice daily at the day of oocyte retrieval ( n = 114). The clinical success rate (31% versus 33%; p = 0.888), miscarriage rate (5.0% versus 3.0%; p = 0.721), ongoing pregnancy rate (30.0% versus 30.0%; p = 1.000), implantation (22.0% versus 24.0%; p = 0.254) and multiple pregnancy rate (5.30% versus 7.20%; p = 0.394) were comparable among the two groups. Serum progesterone levels were significantly lower among the patients receiving dydrogesterone than the control group (13.62 ± 13.83 ng/ml versus 20.66 ± 18.09 ng/ml; p = 0.001). However, there was no statistically significant difference regarding the patients' satisfaction ( p = 0.825) and tolerability (0.790) between the two groups. Our results showed that oral dydrogesterone (40 mg/day) is as effective as vaginal micronized progesterone considering its clinical outcomes and patients' satisfaction and tolerability, for LPS among women undergoing IVF.